0
November 8, 1952, Vol 150, No. 10 >
ARTICLE | November 8, 1952

CAUTION NECESSARY IN THE TREATMENT OF RENAL TUBERCULOSIS WITH ISONIAZID

John K. Lattimer, M.D.
JAMA. 1952;150(10):981-983. doi:10.1001/jama.1952.03680100023007.
Text Size: A A A
Published online
Article
References

Early in 1952 the newspapers reported a new "wonder drug" for tuberculosis. The name of this drug is isoniazid (isonicotinic acid hydrazide). It is at least 600 times more powerful than p-aminosalicylic acid and appears more powerful than streptomycin in killing tubercle bacilli, at least in the test tube. Whether it will be as effective in vivo remains to be seen. Isoniazid does have a place in the treatment of renal tuberculosis. Like streptomycin, it brings about a gradual improvement in the cystoscopic appearance of the lesions of tuberculous cystitis and makes the urine culture sterile for tubercle bacilli in most patients. It is an excellent drug for the treatment of streptomycin-resistant patients. It is not toxic for the nephrons. One patient, who is living on only two renal pyramids, has shown a fall of the blood urea nitrogen level from 100 mg. per 100 cc. down to 25

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

Letters

Submit a Letter
CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Clear Answers | Save For Later
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general journals
BMJ 2010;341:c5893-c1494.
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs

More Listings at
JAMACareerCenter.com >

© 2013 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems